{"altmetric_id":9652421,"counts":{"readers":{"mendeley":30,"citeulike":0,"connotea":0},"total":{"posts_count":23},"twitter":{"unique_users_count":22,"unique_users":["Exome_seq","CancerCureNow","TrueDiagnostics","RielyMD","MaverickNY","Tony_Calles","n8pennell","fararod","lcsmchat","TheseAreMyScars","psych2evidence","susanahprieto","GustaveRoussy","UpstageLungCanc","gonrecondo","Cortot_Lille","FabienReyal","kiyotsuguyoshi2","brunorbastos","JFreemanDaily","krystyna_kk","j2290un"],"posts_count":22},"facebook":{"unique_users_count":1,"unique_users":["643759842335783"],"posts_count":1}},"selected_quotes":["Paper on the transposability of ALK-validated therapeutic approaches to ROS1 secondary mutations","Very practical and useful in a rare population (ROS1+ NSCLC) that would be hard to ever figure out by trials! #LCSM","Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearr\u2026","What a comprehensive figure!","Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor S... #Psychiatry"],"citation":{"abstract":"The identification of molecular mechanisms conferring resistance to Tyrosine Kinase Inhibitor (TKIs) is a key-step to improve therapeutic results for patients with oncogene-addiction. Several alterations leading to Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) resistance to TKI therapy have been described in non-small cell lung cancer (NSCLC). Only two mutations in the ROS1 kinase domain responsible for crizotinib resistance have been described in patients thus far.\nA patient suffering from a metastatic NSCLC harboring an ezrin (EZR)-ROS1 fusion gene developed acquired resistance to the ALK\/ROS1 inhibitor crizotinib. Molecular analysis (Whole exome sequencing, CGH) and functional studies were undertaken to elucidate the mechanism of resistance. Based on this case, we took advantage of the structural homology of ROS1 and ALK to build a predictive model for drug sensitivity regarding future ROS1 mutations.\nSequencing revealed a dual mutation, S1986Y and S1986F, in the ROS1 kinase domain. Functional in vitro studies demonstrated that ROS1 harboring either the S1986Y or the S1986F mutation, while conferring resistance to crizotinib and ceritinib, was inhibited by lorlatinib (PF-06463922). The patient's clinical response confirmed the potency of lorlatinib against S1986Y\/F mutations. The ROS1 S1986Y\/F and ALK C1156Y mutations are homologous and displayed similar sensitivity patterns to ALK\/ROS1 TKIs. We extended this analogy to build a model predicting TKI efficacy against potential ROS1 mutations.\nClinical evidence, in vitro validation and homology-based prediction provide guidance for treatment decision making for patients with ROS1-rearranged NSCLC who progressed on crizotinib.","altmetric_jid":"4f6fa6113cf058f610006efa","authors":["Facchinetti, Francesco","Loriot, Yohann","Cassin-Kuo, Mei-Shiue","Mahjoubi, Linda","Lacroix, Ludovic","Planchard, David","Besse, Benjamin","Auger, Nathalie","Farace, Fran\u00e7oise","Remon, Jordi","Scoazec, Jean-Yves","Andre, Fabrice","Soria, Jean-Charles","Friboulet, Luc","Francesco Facchinetti","Yohann Loriot","Mei-Shiue Cassin-Kuo","Linda Mahjoubi","Ludovic Lacroix","David Planchard","Benjamin Besse","Nathalie Auger","Fran\u00e7oise Farace","Jordi Remon","Jean-Yves Scoazec","Fabrice Andre","Jean-Charles Soria","Luc Friboulet","Mei-Shiue Kuo","Fabrice Andr\u00e9","F. Facchinetti","Y. Loriot","M.-S. Kuo","L. Mahjoubi","L. Lacroix","D. Planchard","B. Besse","F. Farace","N. Auger","J. Remon","J.-Y. Scoazec","F. Andre","J.-C. Soria","L. Friboulet"],"doi":"10.1158\/1078-0432.ccr-16-0917","first_seen_on":"2016-07-13T11:46:46+00:00","funders":["niehs"],"issns":["1078-0432","1557-3265"],"journal":"Clinical Cancer Research","last_mentioned_on":1485244418,"links":["http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27401242?dopt=Abstract&utm_source=dlvr.it&utm_medium=twitter","http:\/\/clincancerres.aacrjournals.org\/content\/early\/2016\/07\/09\/1078-0432.CCR-16-0917.abstract?papetoc","http:\/\/clincancerres.aacrjournals.org\/content\/22\/24\/5983?rss=1","http:\/\/clincancerres.aacrjournals.org\/content\/22\/24\/5983?etoc=","https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27401242","http:\/\/clincancerres.aacrjournals.org\/content\/22\/24\/5983?etoc"],"pdf_url":"http:\/\/clincancerres.aacrjournals.org\/content\/clincanres\/22\/24\/5983.full.pdf","pmid":"27401242","pubdate":"2016-07-11T00:00:00+00:00","publisher":"American Association for Cancer Research","publisher_subjects":[{"name":"Oncology And Carcinogenesis","scheme":"era"}],"scopus_subjects":["Health Sciences","Medicine","Life Sciences","Biochemistry, Genetics and Molecular Biology"],"subjects":["neoplasms"],"title":"Crizotinib-resistant ROS1 mutations reveal a predictive kinase inhibitor sensitivity model for ROS1- and ALK-rearranged lung cancers","type":"article","uri":"http:\/\/clincancerres.aacrjournals.org\/cgi\/doi\/10.1158\/1078-0432.CCR-16-0917","mendeley_url":"http:\/\/www.mendeley.com\/research\/crizotinibresistant-ros1-mutations-reveal-predictive-kinase-inhibitor-sensitivity-model-ros1-alkrear"},"altmetric_score":{"score":14.55,"score_history":{"1y":13.3,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":14.55},"context_for_score":{"all":{"total_number_of_other_articles":8436599,"mean":7.0941864915136,"rank":604528,"this_scored_higher_than_pct":92,"this_scored_higher_than":7831232,"rank_type":"exact","sample_size":8436599,"percentile":92},"similar_age_3m":{"total_number_of_other_articles":261713,"mean":11.78752014428,"rank":27973,"this_scored_higher_than_pct":89,"this_scored_higher_than":233703,"rank_type":"exact","sample_size":261713,"percentile":89},"this_journal":{"total_number_of_other_articles":5493,"mean":6.31812199563,"rank":354,"this_scored_higher_than_pct":93,"this_scored_higher_than":5139,"rank_type":"exact","sample_size":5493,"percentile":93},"similar_age_this_journal_3m":{"total_number_of_other_articles":91,"mean":6.2900444444444,"rank":5,"this_scored_higher_than_pct":94,"this_scored_higher_than":86,"rank_type":"exact","sample_size":91,"percentile":94}}},"demographics":{"poster_types":{"member_of_the_public":16,"researcher":4,"practitioner":2},"users":{"twitter":{"cohorts":{"Members of the public":16,"Practitioners (doctors, other healthcare professionals)":2,"Scientists":4}},"mendeley":{"by_status":{"Unspecified":1,"Professor > Associate Professor":3,"Researcher":9,"Student  > Doctoral Student":2,"Student  > Ph. D. Student":1,"Student  > Postgraduate":2,"Student  > Master":3,"Other":9},"by_discipline":{"Medicine and Dentistry":13,"Chemistry":1,"Energy":1,"Agricultural and Biological Sciences":7,"Biochemistry, Genetics and Molecular Biology":3,"Unspecified":2,"Pharmacology, Toxicology and Pharmaceutical Science":3}}},"geo":{"twitter":{"GB":2,"US":7,"ZA":1,"ES":3,"CA":1,"FR":3},"mendeley":{"US":1,"JP":1}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/Exome_seq\/statuses\/753172674180894720","license":"gnip","citation_ids":[9652421],"posted_on":"2016-07-13T10:22:13+00:00","author":{"name":"Exome-seq","url":"http:\/\/genomics.cruk.cam.ac.uk\/","image":"https:\/\/pbs.twimg.com\/profile_images\/520305836476755970\/1oHrqeyl_normal.png","description":"A PubMed RSS feed for exome, by dlvr.it, http:\/\/bit.ly\/1qv7gmS, and @CIgenomics","id_on_source":"Exome_seq","tweeter_id":"2820127624","geo":{"lt":52.2,"ln":0.11667,"country":"GB"},"followers":629},"tweet_id":"753172674180894720"},{"url":"http:\/\/twitter.com\/CancerCureNow\/statuses\/753220324032774144","license":"gnip","citation_ids":[9652421],"posted_on":"2016-07-13T13:31:34+00:00","author":{"name":"Cure Cancer Now","url":"http:\/\/cancercure-d.blogspot.com\/","image":"https:\/\/pbs.twimg.com\/profile_images\/1128872809\/Hep_G2_Lab_test_normal.jpg","description":"Pure science is what it is taking to defeat cancer. Follow us to be a part of history in the making. Receive only the best information here.","id_on_source":"CancerCureNow","tweeter_id":"193691326","geo":{"lt":null,"ln":null},"followers":8361},"tweet_id":"753220324032774144"},{"url":"http:\/\/twitter.com\/TrueDiagnostics\/statuses\/809414863462264832","license":"gnip","citation_ids":[9652421],"posted_on":"2016-12-15T15:08:36+00:00","author":{"name":"Jerry Lee","url":"http:\/\/www.truediag.com","image":"https:\/\/pbs.twimg.com\/profile_images\/567483990097936384\/6uKJglvi_normal.jpeg","description":"We specialize in providing quick & simple quantitative test systems designed for point-of-care monitoring. Test results in minutes not days..","id_on_source":"TrueDiagnostics","tweeter_id":"317232537","geo":{"lt":32.71533,"ln":-117.15726,"country":"US"},"followers":375},"tweet_id":"809414863462264832"},{"url":"http:\/\/twitter.com\/RielyMD\/statuses\/809453973551927297","license":"gnip","citation_ids":[9652421],"posted_on":"2016-12-15T17:44:00+00:00","author":{"name":"Gregory Riely","url":"http:\/\/www.mskcc.org\/cancer-care\/doctor\/gregory-riely","image":"https:\/\/pbs.twimg.com\/profile_images\/417048782061072384\/_0a_yv3o_normal.jpeg","description":"Medical Oncologist at Memorial Sloan Kettering Cancer Center.  Clinical focus on lung and thymic malignancies","id_on_source":"RielyMD","tweeter_id":"301164011","geo":{"lt":43.00035,"ln":-75.4999,"country":"US"},"followers":1722},"tweet_id":"809453973551927297"},{"url":"http:\/\/twitter.com\/MaverickNY\/statuses\/809454460590260226","license":"gnip","citation_ids":[9652421],"posted_on":"2016-12-15T17:45:56+00:00","author":{"name":"Sally Church","url":"http:\/\/biotechstrategyblog.com","image":"https:\/\/pbs.twimg.com\/profile_images\/901078105544171520\/ovCeTyAL_normal.jpg","description":"Scientist, cancer geek, Londoner, adventurer, explorer, lover of curry, fine wine and football. Science writer at biotech strategy blog","id_on_source":"MaverickNY","tweeter_id":"13649002","geo":{"lt":-29,"ln":24,"country":"ZA"},"followers":16216},"tweet_id":"809454460590260226"},{"url":"http:\/\/twitter.com\/Tony_Calles\/statuses\/809457203094716417","license":"gnip","rt":["RielyMD"],"citation_ids":[9652421],"posted_on":"2016-12-15T17:56:50+00:00","author":{"name":"Dr. Antonio Calles","url":"http:\/\/www.linkedin.com\/profile\/view?id=161163018&trk=nav_responsive_tab_profile","image":"https:\/\/pbs.twimg.com\/profile_images\/725067602297556992\/2Vb_n1K8_normal.jpg","description":"Onc\u00f3logo M\u00e9dico. Trato y empodero pacientes con c\u00e1ncer de pulm\u00f3n. Hospital General Universitario Gregorio Mara\u00f1\u00f3n. Power to the patients. #endlungcancer #lcsm","id_on_source":"Tony_Calles","tweeter_id":"2155543177","geo":{"lt":40.42526,"ln":-3.69063,"country":"ES"},"followers":1480},"tweet_id":"809457203094716417"},{"url":"http:\/\/twitter.com\/n8pennell\/statuses\/809458973350895616","license":"gnip","citation_ids":[9652421],"posted_on":"2016-12-15T18:03:52+00:00","author":{"name":"Nathan Pennell MDPhD","url":"http:\/\/my.clevelandclinic.org\/staff_directory\/staff_display.aspx?doctorid=8882","image":"https:\/\/pbs.twimg.com\/profile_images\/874829435773628421\/DJG4Xz5B_normal.jpg","description":"Thoracic oncologist, with interests in lung cancer and mesothelioma, clinical trials, patient education, and social media. All opinions are my own. #LCSM","id_on_source":"n8pennell","tweeter_id":"205280101","geo":{"lt":41.4995,"ln":-81.69541,"country":"US"},"followers":3784},"tweet_id":"809458973350895616"},{"url":"http:\/\/twitter.com\/fararod\/statuses\/809459138241695745","license":"gnip","rt":["RielyMD"],"citation_ids":[9652421],"posted_on":"2016-12-15T18:04:32+00:00","author":{"name":"Francisco Araujo","image":"https:\/\/pbs.twimg.com\/profile_images\/458352502845358082\/8xumf-Jw_normal.png","description":"Clinical pharmacist \u25cf Pharmaceutical Care \u25cf Amante del arte. Aprendiz. A veces twitteo sobre farmacia.","id_on_source":"fararod","tweeter_id":"525798275","geo":{"lt":37.38241,"ln":-5.97613,"country":"ES"},"followers":1384},"tweet_id":"809459138241695745"},{"url":"http:\/\/twitter.com\/lcsmchat\/statuses\/809472999891943424","license":"gnip","rt":["n8pennell"],"citation_ids":[9652421],"posted_on":"2016-12-15T18:59:37+00:00","author":{"name":"#LCSM Chat","url":"http:\/\/lcsmchat.com","image":"https:\/\/pbs.twimg.com\/profile_images\/527940169698009088\/_RszgddF_normal.jpeg","description":"Join us every other Thursday at 5pm PT\/7pm CT\/8pm ET. @JackWestMD @JFreemanDaily @Louisianagirl91 @DavidCookeMD @LungCancerFaces @BrendonStilesMD #LCSM","id_on_source":"lcsmchat","tweeter_id":"1624156206","geo":{"lt":null,"ln":null},"followers":2181},"tweet_id":"809472999891943424"},{"url":"http:\/\/twitter.com\/TheseAreMyScars\/statuses\/809473485114327041","license":"gnip","citation_ids":[9652421],"posted_on":"2016-12-15T19:01:32+00:00","author":{"name":"These Are My Scars","url":"http:\/\/www.thesearemyscars.com","image":"https:\/\/pbs.twimg.com\/profile_images\/1865373465\/image_normal.jpg","description":"Cancer ass kicker trying to spread a message of hope and change perceptions of the lung cancer community. Posts about my dogs and life may occasionally pop up.","id_on_source":"TheseAreMyScars","tweeter_id":"510713848","geo":{"lt":43.70011,"ln":-79.4163,"country":"CA"},"followers":724},"tweet_id":"809473485114327041"},{"url":"http:\/\/twitter.com\/psych2evidence\/statuses\/809478184139948032","license":"gnip","citation_ids":[9652421],"posted_on":"2016-12-15T19:20:13+00:00","author":{"name":"Psych2 Evidence","image":"https:\/\/pbs.twimg.com\/profile_images\/590651515787993088\/48DTFkEi_normal.jpg","description":"Real-time Evidence-Based Psychiatry Online #ebm #digital #technology #evidence #psychiatry #mentalhealth #futuremedicine Dr Naik @UniofOxford EBHC Student","id_on_source":"psych2evidence","tweeter_id":"3192717557","geo":{"lt":51.75222,"ln":-1.25596,"country":"GB"},"followers":981},"tweet_id":"809478184139948032"},{"url":"http:\/\/twitter.com\/susanahprieto\/statuses\/809517864965328897","license":"gnip","rt":["RielyMD"],"citation_ids":[9652421],"posted_on":"2016-12-15T21:57:53+00:00","author":{"name":"Susana Hern\u00e1ndez","image":"https:\/\/pbs.twimg.com\/profile_images\/796102918059520000\/VasjPLm__normal.jpg","description":"Molecular Biologist, PhD. Hospital Universitario HM Sanchinarro. Laboratorio de Dianas Terap\u00e9uticas (LDT). Madrid (Spain). #lungcancer #MolDx #MolPath #NGS","id_on_source":"susanahprieto","tweeter_id":"796097159259099136","geo":{"lt":40.62862,"ln":-3.16185,"country":"ES"},"followers":122},"tweet_id":"809517864965328897"},{"url":"http:\/\/twitter.com\/GustaveRoussy\/statuses\/809552731937632256","license":"gnip","rt":["RielyMD"],"citation_ids":[9652421],"posted_on":"2016-12-16T00:16:26+00:00","author":{"name":"GustaveRoussy","url":"http:\/\/www.gustaveroussy.fr","image":"https:\/\/pbs.twimg.com\/profile_images\/903289585953898496\/OGovAAEQ_normal.jpg","description":"1er centre de lutte contre le #cancer en Europe \/\/ Soins - Recherche - Enseignement, au service des patients.","id_on_source":"GustaveRoussy","tweeter_id":"151551157","geo":{"lt":46,"ln":2,"country":"FR"},"followers":8454},"tweet_id":"809552731937632256"},{"url":"http:\/\/twitter.com\/UpstageLungCanc\/statuses\/809555339490263041","license":"gnip","rt":["n8pennell"],"citation_ids":[9652421],"posted_on":"2016-12-16T00:26:48+00:00","author":{"name":"Upstage Lung Cancer","url":"http:\/\/www.upstagelungcancer.org\/","image":"https:\/\/pbs.twimg.com\/profile_images\/763904381746081793\/tnO1izFH_normal.jpg","description":"Upstage Lung Cancer is a non-profit organization supporting early detection research using musical entertainment.","id_on_source":"UpstageLungCanc","tweeter_id":"281059849","geo":{"lt":42.33176,"ln":-71.12116,"country":"US"},"followers":1419},"tweet_id":"809555339490263041"},{"url":"http:\/\/twitter.com\/gonrecondo\/statuses\/809564898581692416","license":"gnip","rt":["RielyMD"],"citation_ids":[9652421],"posted_on":"2016-12-16T01:04:47+00:00","author":{"name":"Gonzalo Recondo","image":"https:\/\/pbs.twimg.com\/profile_images\/909824815254601728\/Vz1eLXyM_normal.jpg","description":"Medical Oncologist. PhD student @ IGR.","id_on_source":"gonrecondo","tweeter_id":"743925930264006656","geo":{"lt":46,"ln":2,"country":"FR"},"followers":103},"tweet_id":"809564898581692416"},{"url":"http:\/\/twitter.com\/Cortot_Lille\/statuses\/809665248877834240","license":"gnip","rt":["RielyMD"],"citation_ids":[9652421],"posted_on":"2016-12-16T07:43:32+00:00","author":{"name":"Alexis_Cortot","image":"https:\/\/abs.twimg.com\/sticky\/default_profile_images\/default_profile_normal.png","id_on_source":"Cortot_Lille","tweeter_id":"250794554","geo":{"lt":null,"ln":null},"followers":36},"tweet_id":"809665248877834240"},{"url":"http:\/\/twitter.com\/FabienReyal\/statuses\/809676777203306496","license":"gnip","rt":["RielyMD"],"citation_ids":[9652421],"posted_on":"2016-12-16T08:29:21+00:00","author":{"name":"fabien reyal","url":"http:\/\/www.seintinelles.com","image":"https:\/\/pbs.twimg.com\/profile_images\/902999396081643520\/MNsipsjn_normal.jpg","description":"head of breast cancer, gynecologic cancer and reconstructive surgery, institut curie, paris","id_on_source":"FabienReyal","tweeter_id":"1912331911","geo":{"lt":48.85341,"ln":2.3488,"country":"FR"},"followers":162},"tweet_id":"809676777203306496"},{"url":"http:\/\/twitter.com\/kiyotsuguyoshi2\/statuses\/809710073991700480","license":"gnip","citation_ids":[9652421],"posted_on":"2016-12-16T10:41:39+00:00","author":{"name":"\u30e8\u30c3\u30b7\u30fc","image":"https:\/\/pbs.twimg.com\/profile_images\/716999221375709184\/YYOpmYfx_normal.jpg","description":"MD, Basic Researcher & Artist","id_on_source":"kiyotsuguyoshi2","tweeter_id":"714431915965571072","geo":{"lt":null,"ln":null},"followers":78},"tweet_id":"809710073991700480"},{"url":"http:\/\/twitter.com\/brunorbastos\/statuses\/810186265824006144","license":"gnip","rt":["RielyMD"],"citation_ids":[9652421],"posted_on":"2016-12-17T18:13:52+00:00","author":{"name":"Bruno R. Bastos MD","url":"http:\/\/my.clevelandclinic.org\/staff_directory\/staff_display.aspx?doctorid=13930","image":"https:\/\/pbs.twimg.com\/profile_images\/639488440460034048\/zoT8toHu_normal.jpg","description":"#boardcertified #medicaloncologist @clevelandclinic","id_on_source":"brunorbastos","tweeter_id":"16866052","geo":{"lt":26.70562,"ln":-80.03643,"country":"US"},"followers":384},"tweet_id":"810186265824006144"},{"url":"http:\/\/twitter.com\/JFreemanDaily\/statuses\/810270394557022208","license":"gnip","rt":["n8pennell"],"citation_ids":[9652421],"posted_on":"2016-12-17T23:48:10+00:00","author":{"name":"Janet Freeman-Daily","url":"http:\/\/grayconnections.net\/","image":"https:\/\/pbs.twimg.com\/profile_images\/776896061101133824\/LMqbiiZj_normal.jpg","description":"Writer, speaker, science geek, lung cancer patient\/activist. #LCSM Chat co-mod, #ROS1, #hcldr, MIT & Caltech alum, retired aerospace engineer.","id_on_source":"JFreemanDaily","tweeter_id":"49416874","geo":{"lt":47.60621,"ln":-122.33207,"country":"US"},"followers":3703},"tweet_id":"810270394557022208"},{"url":"http:\/\/twitter.com\/krystyna_kk\/statuses\/810706161293021185","license":"gnip","rt":["n8pennell"],"citation_ids":[9652421],"posted_on":"2016-12-19T04:39:45+00:00","author":{"name":"Krystyna","url":"http:\/\/www.optimalsites.net","image":"https:\/\/pbs.twimg.com\/profile_images\/789650952659795969\/Srg0AoTY_normal.jpg","description":"Mom & COO at Optimal Research. Optimal Research recently launched Just In Time Clinical Trial access for Oncology Patients. #NoPatientLeftBehind #JustInTime","id_on_source":"krystyna_kk","tweeter_id":"780587078413266944","geo":{"lt":35.50069,"ln":-80.00032,"country":"US"},"followers":212},"tweet_id":"810706161293021185"},{"url":"http:\/\/twitter.com\/j2290un\/statuses\/823800916025319424","license":"gnip","rt":["kskvipkskksk"],"citation_ids":[9652421],"posted_on":"2017-01-24T07:53:38+00:00","author":{"name":"J.un","image":"https:\/\/pbs.twimg.com\/profile_images\/825510746687561729\/41wSSSJv_normal.jpg","description":"\u507d\u308a\u306e\u53cb\u3088\u308a\u3042\u304b\u3089\u3055\u307e\u306a\u6575\u306e\u307b\u3046\u304c\u307e\u3057","id_on_source":"j2290un","tweeter_id":"226009627","geo":{"lt":null,"ln":null},"followers":53},"tweet_id":"823800916025319424"}],"facebook":[{"title":"Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=1348357128542714&id=643759842335783","license":"public","citation_ids":[9652421],"posted_on":"2016-12-15T19:00:54+00:00","summary":"Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers","author":{"name":"Lung Cancer Social Media #LCSM Chat","url":"https:\/\/www.facebook.com\/643759842335783","facebook_wall_name":"Lung Cancer Social Media #LCSM Chat","image":"https:\/\/graph.facebook.com\/643759842335783\/picture","id_on_source":"643759842335783"}}]}}